Home › Idiopathic Pulmonary Fibrosis › NCT00373841
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients who are 18 or older * Diagnosis of Idiopathic Pulmonary Fibrosis * Treated at the Simmons Center Exclusion Criteria: * Other Lung Illness
About the study
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Sponsor: University of Pittsburgh · Participants: 500 · Started: 2005-10
Contact the study team
- Michelle MacPherson, MAT · Phone: 412-647-4537
- Michelle Meyers, BSN RN · Phone: 412-692-2149
Official record on ClinicalTrials.gov — NCT00373841
Locations in the U.S.
| Pennsylvania | Michelle F MacPherson, Pittsburgh |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.